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Abstract
Background: Inflammatory processes have been shown to play a role in dementia. To understand this role, we
selected two anti-inflammatory drugs (methotrexate and sulfasalazine) to study their association with dementia risk.
Methods: A retrospective matched case-control study of patients over 50 with rheumatoid arthritis (486 dementia
cases and 641 controls) who were identified from electronic health records in the UK, Spain, Denmark and the
Netherlands. Conditional logistic regression models were fitted to estimate the risk of dementia.
Results: Prior methotrexate use was associated with a lower risk of dementia (OR 0.71, 95% CI 0.52–0.98).
Furthermore, methotrexate use with therapy longer than 4 years had the lowest risk of dementia (odds ratio 0.37,
95% CI 0.17–0.79). Sulfasalazine use was not associated with dementia (odds ratio 0.88, 95% CI 0.57–1.37).
Conclusions: Further studies are still required to clarify the relationship between prior methotrexate use and
duration as well as biological treatments with dementia risk.
Keywords: Dementia, Rheumatoid arthritis, Inflammation, Anti-inflammatory drugs, DMARDs, Methotrexate,
Sulfasalazine, Case-control study, European Medical Information Framework, EMIF
Background
Dementia is one of the largest unmet medical needs, and
with growing numbers of older people in a majority of
countries worldwide, it is set to become an increasing
burden on health services and economies [1]. Despite
considerable progress in the understanding of the patho-
logical lesions associated with the diseases causing the
commonest forms of dementia—Alzheimer’s disease
(AD), vascular dementia, dementia with Lewy bodies
and fronto-temporal dementia—this has not resulted in
therapeutic progress, with multiple trials of compounds
designed for disease modification failing, often at a great
cost [2]. Whilst part of the failure of such trials might be
that they have largely been conducted in patients with
established disease, possibly too late for therapeutic
benefit, there is an increasing realisation that it is likely
forms of dementia are part of a complex set of patho-
logical processes [3]. Understanding these causal path-
ways, and in particular, understanding their timing in
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relation to the onset of dementia, has become a pressing
task in order to progress a novel approach to therapeutic
development.
One of the processes that has come under intensive
investigation in recent years has been that of inflamma-
tion [4–6]. In the analysis of large-scale genome-wide as-
sociation studies, inflammatory pathways such as
complement signalling were consistently identified as al-
tering susceptibility to disease [7, 8]. Post-mortem stud-
ies reflect this association with inflammation, as
microglial and astrocyte numbers are increased and as-
sociated with pathological lesions in disease [9]. How-
ever, such genetic and pathological studies are unable to
distinguish between cause and effect, and it might be
that an inflammatory reaction is part of the defence
mechanism or is contributing to disease progression
[10].
An alternative approach to understanding the direc-
tion and timing of the effect of inflammation in relation
to dementia is to utilise existing observational clinical
data where individuals have received anti-inflammatory
drugs. It was such an approach that first highlighted the
role of inflammation in neurodegeneration when it be-
came apparent that non-steroidal anti-inflammatory
compounds were associated with reduced dementia risk
[11–14].
Many subsequent studies have reproduced this finding,
although trials of such compounds have not been suc-
cessful to date, perhaps because the association is only
seen in those taking medication for extended periods of
time before the onset of dementia [15]. In line with this,
we recently found non-steroidal anti-inflammatory drugs
(NSAIDs) were associated with higher cognitive function
in participants in the UK Biobank cohort study of largely
healthy individuals [16]. Rather than being cognitive en-
hancers, a potential explanation of this finding is that
NSAIDs are reducing the decline in cognitive function
in pre-clinical dementia states. Together, these real-
world observational clinical data studies, therefore, have
made a significant contribution in the following: first,
adding support to the association with inflammation in
disease; second, in adding support suggesting a direction
of that effect; and third, in providing evidence for timing
in relation to disease and therefore informing the design
of clinical studies.
In recent years, more specific anti-inflammatory drugs
have become part of the pharmacotherapy of disorders
such as rheumatoid arthritis, providing an opportunity
to begin to explore the effects of different mechanisms
of inflammation in relation to neurodegeneration [17,
18]. Recognising this, we recently used Clinical Practice
Research Datalink (CPRD), a large dataset derived from
primary care in the UK, to explore the relationship be-
tween different anti-inflammatory compounds and
showed that disease-modifying antirheumatic drugs
(DMARDs), and especially methotrexate, are associated
with a reduction in risk of incident AD [19]. However,
although a relatively large study, the data was from a sin-
gle source and in a single health care context and thus
vulnerable to unanticipated confounding. Here, we set
out to replicate and extend this study across multiple
real-world observational datasets across Europe.
Methods
Study design, setting and source of data
We used a nested retrospective case-control study de-
sign to investigate the association between the use of
disease-modifying antirheumatic drugs (methotrexate
and sulfasalazine) and the incidence of dementia diagno-
sis in routine healthcare data. We used electronic health
records (EHRs) available via the European Medical In-
formation Framework (EMIF; www.emif.eu), a public-
private partnership under the EU Innovative Medicines
Initiative [20]. Methotrexate and sulfasalazine were se-
lected as follows: (1) both drugs are first-line treatments
for rheumatoid arthritis, (2) there is no universally ac-
cepted prescribing preference for these drugs when clini-
cians are faced with the same symptoms and (3) each
drug has a different mechanism of anti-inflammatory ac-
tion [21, 22].
We selected the four databases with primary care, hos-
pital and pharmacy dispensing data sources from across
Europe including Integrated Primary Care Information
(IPCI, 1.8 million) [23], Aarhus University Prescription
Database (AUH, 1.8 million) [24], The Health Informa-
tion Network (THIN, 3.8 million) [25, 26] and Informa-
tion System for Research in Primary Care (SIDIAP, 5.5
million) [27, 28]. Data collection in IPCI, AUH, THIN
and SIDIAP was initiated in 1995, 2000, 2002 and 2006,
respectively. Data collection for this study was from the
first initiation of each database to 2016. Further informa-
tion regarding the databases utilised is provided in the
supplementary information (Table S1).
Participants and study size
The case population is formed by those individuals who
were identified with a first-ever clinical or referral record
of dementia. Further information regarding dementia
definitions and mapping to the different databases in this
study can be found in Perera et al. [29]. The clinical
codes for dementia and other disease variables can be
found in the supporting information (Table S2).
The date at which a patient received the first diagnosis
of dementia was defined as the index date. Up to 25 con-
trols from the initial study population per case were
matched on age (± 2 years), gender and GP practice. Up
to 25 controls were utilised as it was anticipated that
when only including those people with a previous
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history of RA for analysis, the number of controls
would decrease. For the AUH database, information
on GP practice was not available; therefore, controls
were matched to cases on age and gender only. All
individuals included in the analysis had been regis-
tered in their respective database for at least 1 year
before the index date. The index date for controls
(with no dementia diagnosis at their index date or be-
fore) was chosen as the date of dementia diagnosis of
their matched dementia case. From this initial popula-
tion of cases and controls, only those people who
were 50 years or older at the index date were in-
cluded in the study. Furthermore, for each case,
matched controls who had a shorter period before
the index date were removed. Finally, only those
people with a diagnosis of rheumatoid arthritis (RA)
before the index date were included in this study.
Any cases with no remaining controls after applying
exclusion criteria were excluded. A population flow-
chart showing the individual numbers of cases and
controls per dataset is shown in Fig. 1.
Outcome and exposures
The outcome variable was defined as the presence or
absence of a diagnosis of dementia as a binary vari-
able. The diagnosis of dementia was identified in each
database as a first-ever clinical or referral record of
dementia from 1 January 1995 to 31 December 2016.
The diagnosis of rheumatoid arthritis was identified
in each database as a first-ever clinical or referral rec-
ord of rheumatoid arthritis. The exposure variables in
this study were as follows: first prescription of metho-
trexate, if any; first prescription of sulfasalazine, if
any; number of days using methotrexate before index
date; and number of days using sulfasalazine before
the index date. The number of days of drug use was
calculated from the first date of drug use to the last
date of drug use followed by a 12-month gap all be-
fore the index date. Days of use for these drugs were
converted to years by dividing by 365.25 for
consistency. In order to standardise drug treatments
across the different databases if information on dosing
is available, the duration was calculated by dividing
the amount of drug prescribed and the actual dosing
of the individual patient. If information on dosing was
lacking or in case of missing dose, the total amount (per
prescription) is divided by the recommended dosing
according to the Summary of Product Characteristics
(SmPC)/defined daily dose of the respective drug. ATC
drug codes for the two anti-inflammatory medications
were L01BA01 and L04AX03 for methotrexate and
A07EC01 for sulfasalazine. All databases utilised ATC
Fig. 1 The number of individuals initially included in the study and the number of individuals utilised for analysis after exclusions
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codes for methotrexate and sulfasalazine apart from
THIN, which utilises ATC and Read coding.
Potential confounders and model adjustments
Factors considered potential confounders were identified
including age at index date, highest body mass index
measurement (BMI) 2–12 years before the index date
(either BMI or calculated from height and weight mea-
surements) and comorbidities at or before the index date
(stroke and acute myocardial infarction (AMI)). Age was
included as a confounder in all models due to the 2-year
time window used for matching. The highest BMI 2–12
years from the index date was used when available, but
calculated from weight and highest height recorded in
adulthood otherwise. The highest BMI was utilised as
dementia patients are more likely to lose weight leading
up to diagnosis [30]. Any BMI value less than 15 kg/m2
or greater than 60 kg/m2, any weight measurement less
than 30 kg or greater than 150 kg and any height meas-
urement less than 1 m or greater than 2.5 m were con-
sidered measurement errors and not considered.
Cardiovascular disease, including stroke, has been
hypothesised as lying on the causal pathway between RA
and dementia, where people with RA are more at risk of
developing cardiovascular disease such as stroke, which
is then a risk factor for dementia [31, 32]; therefore,
models were used with and without this previous history
of stroke.
We initially performed an unadjusted model and then
we adjusted for age at the index date (years), diagnosis
of stroke before the index date (yes or no), diagnosis of
AMI (yes or no) and BMI, and finally, fully adjusted
models with all confounders but without the previous
stroke diagnosis were performed.
Missing data
The only confounding variable with missing data was
the highest BMI (2–12 years) with missingness of
39.57%. BMI was imputed to avoid the exclusion of pa-
tients and to reduce selection bias. An imputed dataset
was generated using 10 multiple imputations by chained
equations to replace these missing values. We included
all confounders, diagnosis of hypertension, dementia
diagnosis and both drug exposures in the imputation
process.
Statistical methods
A descriptive summary table of the dataset utilised is
presented in Table 1. For the descriptive summary statis-
tics used in this study, an unpaired t test was applied for
normally distributed numerical demographics, a Wil-
coxon unpaired t test was applied for non-normally dis-
tributed numerical demographics and a chi-square test
for categorical demographics was applied.
Conditional logistic regression was used to estimate
the association between drug use and dementia diagno-
sis using R version 3.4.3 and the “survival” package [33].
The data from each database was combined into one
dataset, and a variable indicating which database the
data had originated from was created. We first calcu-
lated the odds ratios (ORs) with 95% confidence inter-
vals (CI) from crude models with no adjustment (model
Table 1 Characteristics of cases and controls (with and without dementia) with rheumatoid arthritis used in this study
Case (with dementia diagnosis) Control (no dementia diagnosis) p value
n 486 641 –
Age at index date (years) 79.8 (± 6.89) 79.5 (± 7.02) 0.522
Gender 86.4% F 87.4% F 0.707
Time since rheumatoid arthritis diagnosis before the index date (years) 6.87 (± 6.29) 7.06 (± 5.92) 0.232
Prescribed with sulfasalazine 40 (8.23%) 57 (8.89%) 0.776
Years of sulfasalazine use before the index date 2.72 (± 3.57) 2.57 (± 3.96) 0.457
Prescribed with methotrexate 123 (25.3%) 178 (27.77%) 0.392
Years of methotrexate use before the index date 2.69 (± 3.06) 3.80 (± 2.44) 0.002
Prescribed with methotrexate or sulfasalazine 19 (3.91%) 25 (3.90%) 1.000
Diagnosed with AMI 26 (5.35%) 34 (5.30%) 1.000
Diagnosed with stroke 37 (7.60%) 64 (10.00%) 0.202
Highest BMI before the index date 28.1 (± 4.99) 28.8 (± 4.90) 0.061
BMI missingness 178 (36.62%) 211 (32.92%) 0.217
Total time in database (years) 7.64 (± 7.82) 7.77 (± 7.66) 0.301
Time in database before the index date (years) 5.16 (± 7.47) 4.62 (± 7.01) 0.027
Case, diagnosis of dementia; control, no diagnosis of dementia. For the calculation of p values to compare the demographics between cases and controls, an
unpaired t test was applied for normally distributed numerical demographics, a Wilcoxon unpaired t test was applied for non-normally distributed numerical
demographics and a chi-square test for categorical demographics was applied
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0). Secondly, we adjusted for all confounders listed in
the “Potential confounders and model adjustments” sec-
tion: age at index date (years), diagnosis of stroke before
the index date (yes or no), diagnosis of AMI (yes or no)
(model 1) and database (multi-level variable). Finally, we
calculated the models with all confounders but without
the previous stroke diagnosis (model 2).
To test the impact of days of use of anti-inflammatory
medications before dementia diagnosis, a new variable
was created based on the days of use of either metho-
trexate or sulfasalazine. For each medication, days of use
before the index date were converted into tertiles for
those taking medication. This created a multi-level vari-
able of the different tertiles based on the days of use of
the medication. Those not taking the medication were as
the reference level in the analysis. The four groups cre-
ated for methotrexate days of use variable were as fol-
lows: group A (reference level n = 740), not taking
methotrexate; group B (n = 52), more than 0 years but
less than or equal to 1.18 years (432.33 days) of metho-
trexate use before the index date; group C (n = 51), those
with greater than 1.18 years but less than or equal to
4.11 years (1500.8 days) of use of methotrexate before
the index date; and finally, group D (n = 51), those taking
methotrexate for more than 4.11 years. The four groups
created for sulfasalazine days of use variable were as fol-
lows: group A (reference level), not taking sulfasalazine;
group B, more than 0 days but less than or equal to 0.49
years (177.5 days) of sulfasalazine use before the index
date; group C, those with greater than 0.49 years but less
than or equal to 2.21 years (808 days) of use of sulfasala-
zine before the index date; and finally, group D, those
taking sulfasalazine for more than 2.21 years. This multi-
level variable, containing the different tertiles based on
days of use for either methotrexate or sulfasalazine, was
then included into the models (instead of the binary
variable indicated if the drug was taken by the patient),
and models 0–2 were calculated using this multi-level
variable.
Results
Descriptive data
A total of 486 subjects with RA who developed dementia
(cases) and 641 matched controls also with RA were in-
cluded. A study participant flowchart is provided show-
ing the impact of each exclusion criterion (Fig. 1).
Characteristics of individuals included in the study are
shown in Table 1. IPCI had 433 patients (37% cases),
SIDIAP 454 (47% cases), THIN 153 (47% cases) and
AUH 87 (48% cases).
Cases and controls were balanced in terms of most of
the measured variables (Table 1). Additionally, although
the total time in the database between cases and controls
did not differ, controls had slightly shorter time in the
databases compared with the cases with time in the
database before the index date at 5.16 years for cases and
4.62 years for controls. However, this difference is not
present in three databases (AUH, SIDIAP and THIN)
when considering the individual databases. The differ-
ence is due to the IPCI dataset having more cases with a
higher number of controls who have a shorter time be-
fore the index date. Other covariates did not differ be-
tween cases and controls to a statistically significant
extent. The total range of ages at the index date for cases
and controls in Table 1 was 50–97 years and 52–97
years, respectively. The total range of methotrexate use
in years was 0.074–18.8 years, and the total range of
sulfasalazine use in years was 0.036–19.5 years. For a de-
tailed breakdown of the duration of methotrexate and
sulfasalazine use across 5-year age brackets for dementia
cases, see the supporting information (Table S3).
Association between DMARDs use and dementia
diagnosis
For the unadjusted model, there was a trend, although
not statistically significant, towards reduced risk of de-
mentia with methotrexate use (OR 0.76, 95% CI 0.56–
1.03). Using adjusted models, we found a statistically sig-
nificant association with methotrexate but no association
with sulfasalazine in relation to dementia diagnosis. For
models 1 and 2, similar ORs were obtained for metho-
trexate (0.71, 95% CI 0.52–0.98; 0.71, 95% CI 0.52–0.98)
both achieving statistical significance (Table 2). As
models 1 and 2 show similar results, we conclude that
there is no significant effect of stroke on the relationship
between drug exposure and dementia onset. A forest
plot showing the results of Table 2 can be found in the
supplementary information (Figure S1).
We then investigated the number of days of use of
methotrexate and sulfasalazine before dementia diagno-
sis. The results showing the number of days of use of
methotrexate in tertiles with dementia diagnosis are
shown in Fig. 2.
We found a clear treatment time effect (even though
tertiles 1 and 2 were not significant) with those taking
methotrexate for the longest period (greater than 4.11
years) prior to the index date having the greatest effect
on dementia risk for all models (Fig. 2). The results indi-
cate that the association is only significant for those who
took methotrexate for a minimum of over 4 years of
treatment. For the unadjusted model, those who took
methotrexate for a minimum of 4.11 years achieved an
odds ratio of 0.39 (95% CI 0.18–0.84, p value 0.015) with
similar odds ratios obtained for models 1 and 2 of 0.38
(95% CI 0.18–0.84, p value 0.016) and 0.37 (95% CI
0.17–0.79, p value 0.011), respectively.
The full table of results can be found in the supple-
mentary information (Table S4). We then repeated this
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analysis for sulfasalazine finding no significant associ-
ation between duration of prescription and risk of de-
mentia (Table 3). However, it is interesting to note that
the general trend (even though all values are not signifi-
cant) indicating longer use is associated with increased
dementia risk.
Discussion
In this uniquely large and geographically diverse sample
using four European harmonised electronic health rec-
ord datasets using the EMIF platform, we found evi-
dence that in adults older than 50 years of age with
rheumatoid arthritis, taking methotrexate was associated
with a lower risk of a subsequent dementia diagnosis,
specifically recorded methotrexate use for more than 4
years. We also investigated sulfasalazine use but found
no such association.
However, the lack of association between sulfasalazine
and dementia could also be attributed to the low fre-
quency of sulfasalazine usage in these databases, and this
could provide an account for the lack of statistically sig-
nificant reduction in dementia risk.
The data used in this study does not permit any con-
clusive causal information regarding the biological
mechanisms of the anti-inflammatory properties of
methotrexate relative to sulfasalazine in relation to de-
mentia risk. However, by identifying the potential mech-
anisms and how they differ between the two drugs will
be helpful in pointing to future directions for under-
standing the underlying mechanisms in basic research of
inflammation and dementia, which would need to be
understood before any such compounds would be tested
in intervention trials. The exact mechanism of action of
methotrexate or sulfasalazine is not well understood;
however, several overlapping and distinct mechanisms
have been proposed. For methotrexate, these mecha-
nisms include folate-dependent processes, adenosine
signalling, inhibition of methyl-donor production, gener-
ation of reactive oxygen species, alteration of cytokine
profiles and downregulation of adhesion molecule
Table 2 Unadjusted and adjusted model showing the association between methotrexate and sulfasalazine treatment and dementia
diagnosis in people with rheumatoid arthritis using conditional logistic regression
Drug Model 0 Model 1 Model 2
Unadjusted OR (95% CI) p value Adjusted OR (95% CI) p value Adjusted OR (95% CI) p value
Methotrexate 0.76 (0.56–1.03) 0.076 0.72 (0.52–0.98) 0.036 0.71 (0.52–0.98) 0.034
Sulfasalazine 0.88 (0.57–1.36) 0.56 0.89 (0.57–1.38) 0.60 0.88 (0.57–1.37) 0.57
Model 0, no adjustment; model 1, adjustment for age, BMI, stroke and AMI; model 2, same as model 1 but not including diagnosis of stroke. OR odds ratio for
dementia risk
Fig. 2 Association between methotrexate years of use and dementia diagnosis in people with rheumatoid arthritis using conditional logistic regression
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expression, eicosanoids and matrix metalloproteinases
[34]. For sulfasalazine, it is still not clear whether the
parent drug and/or its main metabolites (sulfapyridine
and mesalazine) are responsible for the beneficial effects
in rheumatoid arthritis [35, 36]. Based on in vitro and
in vivo studies, sulfasalazine appears to exert effects on
inflammatory cell function, cytokine and antibody pro-
duction, inhibition of folate-dependent enzymes, inhib-
ition of synovial neovascularization and free radical
scavenging activity [37]. Both methotrexate and sulfa-
salazine appear to be involved in adenosine signalling
[38–40] and affect T cell activity via CD8 and inhibit B
cells by interrupting Ig synthesis whereas only metho-
trexate interferes with IL-2, and only sulfasalazine causes
prostaglandin inhibition. There is evidence in the litera-
ture that methotrexate is involved in the inhibition of in-
flammatory cell proliferation, interference with T cell
activity and cytokine secretion, and augmented release
of adenosine, macrophage and polymorphonuclear
leukocyte inhibition where this has not been shown with
sulfasalazine [37, 38]. These drugs are involved in over-
lapping and distinct mechanisms, and this could poten-
tially explain why we did not see an association between
sulfasalazine and dementia risk. However, the lack of cu-
mulative measures reflecting inflammatory disease bur-
den precludes definitive conclusions regarding the causal
relationship between methotrexate use, reduced inflam-
mation and lowered risk of dementia.
Investigations of anti-inflammatory DMARDs on de-
mentia risk have reported conflicting results. Judge et al.
[19] showed a decreased risk of dementia with metho-
trexate use. Using the UK Clinical Practice Research
Datalink, Judge et al. found that DMARD users were at
reduced risk of dementia (hazard ratio 0.60; 95% confi-
dence interval 0.42–0.85), and the effect was strongest in
methotrexate users (hazard ratio 0.52; 95% confidence
interval 0.34–0.82). Our study extends these findings by
utilising datasets across multiple countries as well as
highlighting the stronger associations of longer metho-
trexate use with reduced dementia risk.
Judge et al. contradict the study carried out by
Chou et al. [41]. In this study, using the Taiwan
National Health Insurance Research Database, people
taking non-biologic DMARDs had a higher risk of
any dementia type (AD, vascular) compared with
people who did not take DMARDs or used biologic
DMARDs. This study used a cut-off age of people
equal or older than 20 years; however, the majority of
people used in the analysis were older than 65 (>
80%). Furthermore, this study also showed that the
numbers of days of use of either methotrexate or
sulfasalazine increased dementia risk. The contradict-
ory results from this study could be for a number of
reasons, firstly differences in geographic locations
(European versus Asian). Further studies are still re-
quired to clarify the relationship between prior
methotrexate use and duration as well as dementia
risk with the use of other DMARDs, particularly
biological therapies. Future experimental studies are
warranted to determine the specific mechanisms for
the protective association between prior methotrexate
treatment and dementia.
Our study has several strengths. First, the use of mul-
tiple routine EHR databases under the EMIF platform
has allowed for aggregation and harmonisation of huge
volumes of suitable data to investigate the association
between dementia and inflammatory exposures. The ac-
cess to large amounts of data has meant that we have
been able to select people with a relatively rare condition
such as RA and have sufficient numbers of incident
cases of dementia. By only including people who had RA
in this study, we have increased the likelihood of cases
and controls being comparable rather than just compar-
ing medication use or not within the total samples and
therefore could consider the effect of medications and
dementia risk. In this study, we used a matched popula-
tion, which minimises bias due to confounding by indi-
cation but also limits the generalizability of the findings.
In particular, we only utilised those people with RA also
limiting our generalizability. In this study, four EHR
Table 3 Unadjusted and adjusted model showing the association between days of use of sulfasalazine treatment and dementia
diagnosis in people with rheumatoid arthritis using conditional logistic regression
Variable group Model 0 Model 1 Model 2
Unadjusted OR (95%
CI)
p
value
Adjusted OR (95%
CI)
p
value
Adjusted OR (95%
CI)
p
value
No sulfasalazine use Ref Ref Ref
Sulfasalazine use for 0.49 years (first tertile) 0.60 (0.28–1.31) 0.20 0.65 (0.30–1.41) 0.28 0.65 (0.30–1.41) 0.28
Sulfasalazine use for 0.49 to 2.21 years (second
tertile)
0.93 (0.45–1.93) 0.85 0.94 (0.45–1.95) 0.86 0.89 (0.43–1.85) 0.76
Sulfasalazine use for > 2.21 years (third tertile) 1.21 (0.58–2.51) 0.62 1.16 (0.55–2.44) 0.69 1.19 (0.57–2.48) 0.65
Model 0, no adjustment; model 1, adjustment for age, BMI, stroke and AMI; model 2, same as model 1 but not including stroke variable. OR odds ratio for
dementia risk
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databases, primary care and hospital-based, from four
European countries, were utilised, giving general applic-
ability across multiple European countries. Second, we
followed an EMIF harmonisation process where a single
protocol was utilised for the study, single format of data
extracts, semantic harmonisation process ensuring com-
parability of clinical code lists and a statistical analysis
plan with the same statistical analysis steps applied on
the extracted data ensuring consistency in results.
Our study also had limitations. We only investigated
the effect of two anti-inflammatory drugs, methotrexate
and sulfasalazine, without considering the impact of
other drug treatments potentially administered such as
biologics and concomitant use of biologics and other
non-biologic anti-inflammatory medications. Therefore,
confounding by indication could exist as the severity of
RA may impact the choice of medication where metho-
trexate and sulfasalazine are usually the first-line treat-
ments for RA. Therefore, the characteristics of patients
receiving methotrexate versus sulfasalazine could be dif-
ferent due to the underlying disease severity (as mea-
sured by the Disease Activity Score 28 (DAS28),
presence/absence of joint erosions and other inflamma-
tory biomarkers) and degree of inflammation and there-
fore could contribute to confounding by indication.
However, Judge et al. [19] used propensity score match-
ing to account for confounding by indication and
showed similar results to ours regarding a reduced risk
of dementia with methotrexate use. Furthermore, drug
adherence could affect the results with drug side effects
which could affect the compliance of taking the medica-
tions utilised in this study. Additionally, discontinuation
of drug treatment could impact the degree of undefined
inflammation leading up the onset of dementia in cases.
Based on the study design, it is feasible that some pa-
tients had continuous treatment and others did not.
Additionally, cases and controls who used both metho-
trexate and sulfasalazine were included in the analysis,
adding another potential confounder that weakens the
overall statistical association between methotrexate use
and lowered risk of dementia. Owing to the observa-
tional nature of the study, there remains the potential
for residual confounding that could attenuate or explain
the observed associations, due to unmeasured variables
such as arthritis disease severity, health, concomitant
therapy and lifestyle effects such as physical activity and
alcohol consumption. However, in spite of this, the data
used for this study does reflect the wider rheumatoid
arthritis patient population in terms of gender distribu-
tion [42].
Regarding the clinical diagnosis of dementia, there is
the possibility of non-uniform case assignment. How-
ever, it is reasonable that all countries (the UK, Spain,
Denmark and Holland) have dementia assessment
services and the potential for specialist diagnoses (which
are more likely to vary in coverage within rather than
between sites) and that this will be more likely to have
obscured our findings through case heterogeneity and
measurement error rather than give rise to false-positive
findings. Furthermore, the diagnosis of dementia is usu-
ally assessed by a general practitioner and not by a stan-
dardised research diagnosis, which may differ depending
on the type of dementia, so this may attenuate the asso-
ciations. We also defined dementia to encompass any
type of dementia including Alzheimer’s disease and vas-
cular dementia; therefore, it might be possible that a
specific subtype of dementia is driving the association.
Further work, from this study, would be to establish
the following: firstly, if other anti-inflammatory medica-
tions such as hydroxychloroquine and leflunomide affect
dementia risk; secondly, whether biological anti-
inflammatories reduce dementia risk; thirdly, if these as-
sociations are effected by NSAID and prednisone usage;
and finally, whether methotrexate treatment affects the
risk in the different dementia subtypes.
Conclusion
In summary, this case-control study across multiple
EHR databases found that prior methotrexate use, but
not sulfasalazine use, was associated with dementia diag-
nosis even after adjusting for patients’ demographics and
comorbidities. Furthermore, we showed that there is a
gradual decrease against dementia risk the longer the
use of methotrexate before the index date. These find-
ings are relevant from a public health perspective since
they highlight the potential of methotrexate to protect
against dementia; however, the mechanism behind this
remains to be elucidated.
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